心血管

订阅

MedSci主页 / 所有栏目 / 心血管

危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高

2020-07-12 Allan MedSci原创

利托那韦洛匹那韦心动过缓Covid-19
关注

接受抗逆转录病毒药物洛匹那韦和利托那韦联合治疗的危重COVID-19患者易发生心动过缓和心律缓慢。

一项在《Circulation: Arrhythmia and Electrophysiology》上发表的最新研究显示，接受抗逆转录病毒药物洛匹那韦和利托那韦联合治疗的危重COVID-19患者易发生心动过缓和心律缓慢。

抗逆转录病毒药物洛匹那韦（LPV）和利托那韦（RTV）的组合先前已用于治疗SARS-Cov-1和MERS-Cov的患者，以及HIV-1的患者。在HIV-1患者中，也存在心动过缓的风险。

该研究纳入了41例危重COVID-19患者，患者每天两次接受200 mg LPV和50 mg RTV治疗，持续10天。所有患者均接受连续心电图（ECG）监测。研究人员记录了经LPV+RTV联合治疗的心动过缓风险。研究结果表明，22％患者的心动过缓超过24小时；心动过缓发生在治疗开始至少48小时后，表明药物可能引起心动过缓；接受治疗72小时后，心动过缓患者血液里的RTV浓度较高。

心动过缓患者的心律低于60次/分钟，持续超过24小时，心动过缓可能会导致心衰、晕厥、胸痛和低血压。在某些人中，心动过缓不会引起任何症状。

 

原始出处：

https://www.firstwordpharma.com/node/1739654?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 zhangph

    #COVID-19患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 zhaozuguo

    #联合治疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 cathymary

    #洛匹那韦#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 xuqianhua

    #心动过缓#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 sunyl12

    #利托那韦#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1297461, encodeId=28b5129e46195, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455811, encodeId=3292145581108, content=<a href='/topic/show?id=c8bd651103a' target=_blank style='color:#2F92EE;'>#洛匹那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65110, encryptionId=c8bd651103a, topicName=洛匹那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74e5737171, createdName=cathymary, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554145, encodeId=fc4e1554145f4, content=<a href='/topic/show?id=33c950903aa' target=_blank style='color:#2F92EE;'>#心动过缓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50903, encryptionId=33c950903aa, topicName=心动过缓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=424914510212, createdName=xuqianhua, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Tue Jul 14 08:52:37 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 sunyl12

    #利托那韦#

    0

相关资讯

Antimicrob Agents Ch：HIV儿童：洛匹那韦-利托那韦与MDR-TB常用药联用时相互作用如何？

2018年1月，发表在《Antimicrob Agents Chemother》上的一项研究，对洛匹那韦-利托那韦与一线和二线抗结核药物在艾滋病毒（HIV）感染儿童治疗耐多药结核病中的药物动力学和药物相互作用进行了考察。

Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究

Eiger制药是一家专注于罕见疾病靶向疗法研发的生物制药公司，Eiger近日宣布第一名患者入组了II期LIFT临床试验，该试验在美国国立卫生研究院（NIH）的国家糖尿病、消化和肾脏疾病研究所（NIDDK）中进行。

Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效

研究认为，早期三重抗病毒治疗在缓解轻至中度COVID-19患者的症状、缩短病毒脱落时间和住院时间方面安全且有效，以干扰素β-1b为基础的双重抗病毒治疗可能成为未来临床研究的方向。

CPP：利托那韦显著改变多西他赛暴露水平

目前，HIV阳性患者中非AIDS诱发的肿瘤(NADC)发生率多于AIDS诱发的肿瘤发生率。NADC的治疗可能因抗逆转录病毒药物与化学疗法之间的药物相互作用而具有复杂性。多西他赛是一种广泛被应用的抗肿瘤药物，可用于治疗NADC。美国学者研究发现，CYP3A4的抑制剂可显著改变多西他赛的暴露水平。论文2014年4月1日在线发表于《癌症化疗与药理学》（Cancer Chemotherapy and Ph

NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果

在住院的严重Covid-19成人患者中，在标准护理之外的洛匹那韦-利托那韦治疗没有观察到任何益处。

Lancet：洛匹那韦–利托那韦加上拉米夫定对HIV-1病毒抑制的维持

    背景  该研究的目标是评估洛匹那韦–利托那韦双重治疗以及拉米夫定和洛匹那韦–利托那韦加上HIV-1病毒抑制的两个核苷（酸）的三联双治疗的非劣效性。    方法  在这项随机，开放标签，非劣效性试验中，研究人员从西班牙和法国医院的32 HIV单位招募了患者。符合条件的患者为感染HIV的成人（年龄≥18岁），HIV-1 RNA每毫升少

拓展阅读

Critical Care Medicine：气道压力释放通气模式在COVID-19导致急性呼吸 衰竭的患者中的应用：一项单中心随机对照试验

与小潮气量机械通气相比，APRV通气模式并未缩短重症新冠肺炎机械通气患者的机械通气时间，也未改善患者的其他临床结局。

Radiology：超极化氙气MRI显示长期COVID患者的肺部异常

胸部X线片（CXR）是诊断急性COVID-19肺炎最常用的成像方式，对于需要入院治疗的患者，通常会在急性感染三个月后重复检查。

Radiology：基于胸部CT的COVID-19肺炎后1年的预后评估

胸部CT对疾病监测至关重要，时间是充分评估肺部恢复能力的关键因素。

Am J Resp Crit Care：半乳糖凝集素-3抑制剂治疗COVID-19肺炎

在COVID-19肺炎中，吸入GB013治疗的耐受性良好，达到了临床相关的血浆浓度。该研究的数据支持更大规模的临床试验来明确GB013的临床疗效。

European Radiology：如何实现影像学的标准COVID-19全自动预测？

放射组学是一种利用数学算法量化医学成像中病变的表型特征的方法，可用于预测疾病的严重程度和进展。

Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定，它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。